Letrozole: Evidence-Based Review

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

**Letrozole**, a highly selective, non-steroidal aromatase inhibitor, has profoundly impacted the landscape of endocrine therapy for breast cancer and has em...

Letrozole, a highly selective, non-steroidal aromatase inhibitor, has profoundly impacted the landscape of endocrine therapy for breast cancer and has emerged as a cornerstone in fertility treatment. Its mechanism of action, centered on potent estrogen suppression, underpins its efficacy in hormone receptor-positive breast cancer, where estrogen fuels tumor growth. Beyond oncology, letrozole has revolutionized ovulation induction, particularly for women with polycystic ovary syndrome (PCOS), by offering a superior alternative to traditional fertility drugs. The extensive clinical evidence supporting letrozole's diverse applications has solidified its position as a critical medication in modern medicine. This review aims to synthesize the robust body of evidence, highlighting key clinical trials, efficacy data, and comparative studies that define letrozole's role in breast cancer management and reproductive health. Understanding the scientific foundation and clinical outcomes associated with letrozole is essential for healthcare professionals and patients navigating complex treatment decisions.

What Is Letrozole?

Letrozole is an oral medication classified as a third-generation, non-steroidal aromatase inhibitor. It functions by reversibly binding to the aromatase enzyme, which is responsible for the final step in the biosynthesis of estrogens from androgens. This competitive inhibition effectively blocks the production of estrogen throughout the body, leading to a significant reduction in circulating estrogen levels. Letrozole is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women, including adjuvant, extended adjuvant, and first-line advanced settings. Additionally, it is widely used off-label as a first-line agent for ovulation induction in women with infertility, particularly those with anovulatory conditions like PCOS.

How It Works

The fundamental mechanism of action of letrozole involves the potent and selective inhibition of the aromatase enzyme. Aromatase, a member of the cytochrome P450 superfamily, is responsible for the crucial step of converting androgens (such as androstenedione and testosterone) into estrogens (estrone and estradiol). This enzymatic process occurs in various peripheral tissues, including adipose tissue, muscle, liver, and in the ovaries, adrenal glands, and breast tissue.

Letrozole is a non-steroidal competitive inhibitor of aromatase. This means it reversibly binds to the heme moiety of the aromatase enzyme. By occupying the active site, letrozole prevents the natural androgen substrates from binding and undergoing aromatization. This competitive binding leads to a significant and dose-dependent reduction in circulating estrogen levels, often by more than 90%. This profound estrogen suppression is central to its therapeutic effects.

In hormone receptor-positive breast cancer, where estrogen acts as a growth factor for tumor cells, the reduction in estrogen levels starves the cancer cells, inhibiting their proliferation and promoting apoptosis. This leads to tumor regression and a reduced risk of recurrence.

In ovulation induction, particularly for conditions like Polycystic Ovary Syndrome (PCOS), letrozole's mechanism is slightly different. The transient reduction in estrogen levels removes the negative feedback on the hypothalamus and pituitary gland. This, in turn, leads to an increase in the pulsatile release of gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to secrete more follicle-stimulating hormone (FSH). The elevated FSH levels then promote the growth and maturation of ovarian follicles, ultimately leading to ovulation.

Key Benefits

The clinical benefits of letrozole are well-documented and span its primary indications in oncology and reproductive medicine:

Clinical Evidence

The clinical evidence supporting the efficacy and safety of letrozole is extensive and has been established through numerous large-scale, randomized controlled trials.

Breast Cancer Treatment:

Adjuvant Therapy (BIG 1-98 Trial): The Breast International Group (BIG) 1-98 trial was a pivotal study involving over 8,000 postmenopausal women with hormone receptor-positive early breast cancer. It compared 5 years of letrozole, 5 years of tamoxifen, and sequences of both. The trial demonstrated that letrozole monotherapy significantly improved disease-free survival (DFS) compared to tamoxifen monotherapy. The 5-year DFS rate was 84.0% for letrozole versus 81.4% for tamoxifen (Hazard Ratio [HR] 0.82; 95% CI 0.73-0.93; P=0.002) BIG 1-98 Collaborative Group, 2005.

Extended Adjuvant Therapy (MA-17 Trial): The MA-17 trial investigated the benefit of extending adjuvant endocrine therapy with letrozole after 5 years of tamoxifen in postmenopausal women with early breast cancer. The study showed a significant improvement in DFS with letrozole compared to placebo, with a 43% reduction in the risk of recurrence (HR 0.57; 95% CI 0.43-0.75; P<0.001) Goss et al., 2003. This trial established letrozole as a standard option for extended adjuvant therapy.

First-Line Advanced Breast Cancer: Letrozole has also shown superior efficacy as first-line treatment for advanced hormone receptor-positive breast cancer in postmenopausal women compared to tamoxifen, demonstrating longer time to progression and higher objective response rates Mouridsen et al., 2003.

PPCOS II Trial: The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial was a large, multicenter, randomized controlled trial comparing letrozole to clomiphene citrate for ovulation induction in women with PCOS. The study found that letrozole resulted in a significantly higher live birth rate (27.5%) compared to clomiphene (19.1%) (P<0.001), with a lower incidence of multiple gestations Legro et al., 2014. This trial solidified letrozole's position as a first-line treatment for ovulation induction in PCOS.

Meta-Analyses: Numerous meta-analyses have consistently supported letrozole's superiority or non-inferiority to clomiphene citrate in terms of live birth rates and ovulation rates in women with PCOS, often with a more favorable side effect profile and lower risk of ovarian hyperstimulation syndrome (OHSS) Franik et al., 2018.

Standard Dose: The recommended dose for all approved breast cancer indications (adjuvant, extended adjuvant, and first-line advanced) is 2.5 mg orally once daily. It can be taken with or without food, but consistency in timing is often advised.

Duration: For adjuvant therapy, treatment typically continues for 5 years. For extended adjuvant therapy, it may be prescribed for an additional 5 years after initial tamoxifen treatment. For advanced disease, treatment continues until disease progression or unacceptable toxicity.

Standard Protocol: The typical starting dose is 2.5 mg orally once daily for 5 days, usually initiated on day 3, 4, or 5 of the menstrual cycle. If ovulation does not occur, the dose may be increased to 5 mg or 7.5 mg daily for 5 days in subsequent cycles. Treatment cycles are generally limited to 3-6 cycles.

Timing: The short half-life of letrozole allows for a brief treatment window, with ovulation typically occurring 5-10 days after the last dose. This protocol aims to induce a more physiological follicular development compared to other ovulation induction agents.

Monitoring: For breast cancer patients, regular clinical assessments, imaging, and bone mineral density (BMD) monitoring are crucial. For fertility patients, ultrasound monitoring is often used to track follicular growth and endometrial thickness, and blood tests may confirm ovulation.

Individualization: Dosing and treatment duration should always be individualized based on patient response, tolerability, and specific clinical goals. Consultation with a specialist is essential.

Vasomotor Symptoms: Hot flushes (up to 33%) and sweating are very common, directly resulting from reduced estrogen levels.

Musculoskeletal Symptoms: Arthralgia (joint pain, up to 22%), myalgia (muscle pain), and bone pain are frequently reported and can sometimes be significant, impacting quality of life. This can include stiffness, particularly in the hands, knees, and hips.

Fatigue: A general feeling of tiredness and lack of energy is common (up to 11%).

Headache and Dizziness: These neurological symptoms can occur (headache up to 10%).

Gastrointestinal Issues: Nausea, abdominal pain, and constipation or diarrhea are possible.

Weight Gain: Some women may experience an increase in weight.

Hair Thinning: Less common, but can occur.

Serious Side Effects & Long-Term Concerns:

Bone Mineral Density (BMD) Loss and Osteoporosis: This is a significant long-term concern. Chronic estrogen deprivation can lead to accelerated bone loss, increasing the risk of osteopenia and osteoporosis, and consequently, fractures. Regular BMD monitoring (e.g., DEXA scans) and prophylactic measures (calcium, vitamin D, bisphosphonates) are often recommended BIG 1-98 Collaborative Group, 2005. The risk of fractures is generally higher with aromatase inhibitors compared to tamoxifen.

Cardiovascular Events: Some studies have suggested a potential for increased risk of cardiovascular events, including hypercholesterolemia (elevated cholesterol levels), with aromatase inhibitors. Patients with pre-existing cardiovascular risk factors should be monitored closely.

Thromboembolic Events: While the risk is generally lower than with tamoxifen, there is still a small risk of blood clots.

Liver Function Abnormalities: Rare instances of elevated liver enzymes have been reported.

Side Effects in Fertility Treatment:

When used for ovulation induction, letrozole is typically used for short durations (5 days), and therefore, long-term side effects like significant bone loss are less of a concern. Common side effects are generally mild and transient:

Hot Flushes: Similar to breast cancer patients, but usually less severe and transient.

Headache and Dizziness: Frequently reported.

Fatigue: Mild tiredness.

Nausea: Can occur.

Ovarian Hyperstimulation Syndrome (OHSS): While letrozole has a lower risk of OHSS compared to clomiphene citrate, it is still a potential, though rare, complication, especially in sensitive individuals. The transient nature of estrogen suppression with letrozole contributes to its lower OHSS risk.

Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: This is the primary approved indication. It is used as adjuvant therapy for early breast cancer, extended adjuvant therapy after initial tamoxifen treatment, and first-line treatment for advanced disease.

*